Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, short-term liraglutide treatment led to significant weight loss in obese women with newly diagnosed PCOS and a higher metabolic risk profile compared to metformin.

This review discusses pharmacological options for managing obesity in women with PCOS and highlights the need for further research on emerging therapies and personalized treatment approaches; it reports no new clinical results.

GLP-1 therapies can cause hair loss, but hair often regrows after stopping or reducing the drug.

GLP-1 and GLP-1/GIP agonists may increase the risk of hair loss.

This study analyzed safety data for semaglutide, liraglutide, and tirzepatide from the EudraVigilance database, identifying potential safety signals not listed in current SmPCs, such as optic ischemic neuropathy and pancreatitis, underscoring the importance of ongoing pharmacovigilance.